Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neuroscience -- Ignore unavailable to you. Want to Upgrade?

To: dalroi who wrote (243)	1/5/2003 9:51:44 AM
From: scott_jiminez	Respond to of 278

<<3mg group seems to do beter then the 6mg or is this just a statistical flucke >> I read the data as 3 mg and 6 mg being statistically equivalent since they both differ from placebo at the same level of significance. Recall there is always scatter in data: thus the 3 mg dose results are probably something like 0.7 +/- 0.2 and the 6 mg dose is likely 1.1 +/- 0.25. In other words, there overlap in the results from the 2 doses (i.e. there's no statistical 'fluke' because there no statistical difference). These data suggest the antibody dose had already maxed out at 3 mg.